University of Pittsburgh Health Sciences eLearning Environment Internet-based Studies in Education and Research
INTRODUCTION
ABIM MOC Activity ID
5/1/2018 - Medical Grand Rounds: Cardiovascular Effects of Incretin-based Anti-Diabetic Therapies
QUIZ
EVALUATION
CERTIFICATE
Credit Hours: CME 1.00
Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.
Upon completion of this activity, participants should be able to:
- Know which incretin-based therapies cause weight loss and reduce cardiovascular mortality.
- Name three differences between GLP-1 analogs and DPP4 inhibitors.
- Describe a potential drug-drug interaction between ACE inhibitors and DPP inhibitors.
- Name potential side effects of GLP-1 analogs.
- UKPDS study group Lancet 1998; 352: 854
- Nauck M et al. Diabetologia 1986
- Drucker and Nauck Lancet 2006
- Knudsen LB et al. J Med Chem 2000
- Yamamoto et al J Clin Invest 2002
- Trahair et al J Clin Endocrinol Metab 2014
- Wu et al Diabetic Med 2014
Dr. Brown receives grant support from NIH, AHA, Novo Nordisk, Shire Pharmaceuticals. She is a consultant with Novartis Pharmaceuticals, Shire Pharmaceuticals, and Viamet Pharmaceuticals, Alnylam Pharmaceuticals
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity.
The University of Pittsburgh is an affirmative action, equal opportunity institution.